Floatz logo

[111in]-fpi-2058

NTSR1 Expressing Solid Tumours

3B Pharmaceuticals GmbHradiopharmaceuticalPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the NTSR1 Expressing Solid Tumours cohort.

Asset / SponsorPhaseRating
[225]-fpi-2059
3B Pharmaceuticals GmbH
Phase 1CC

Same molecule, other indications

[111in]-fpi-2058 is also rated in:

prostate neuroendocrine neoplasmDormant
CC
Indicative ·
43 / 100
View asset →
head and neck squamous cell carcinomaDormant
CC
Indicative ·
41 / 100
View asset →
Ewing sarcomaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →